fig3

Figure 3. Drug-specific transcriptional reprogramming of metabolism pathways in chemoresistant HR+/HER2- BC. (A and B) Heatmaps of metabolism-related genes consistently dysregulated (logFC < -0.5 or > 0.5; FDR < 0.05) in taxane-resistant (A) and anthracycline-resistant (B) cell models; (C-F) Pathway enrichment analysis highlighting dysregulated metabolic pathways in MCF-7 Doc-R (C), ZR-75-1 Pac-R (D), MCF-7 Epi-R (E), and ZR-75-1 Epi-R (F) cells compared with their respective parental counterparts. HR+/HER2-: Hormone receptor-positive/human epidermal growth factor receptor 2-negative; BC: breast cancer; FDR: false discovery rate; Doc-R: docetaxel-resistant; Pac-R: paclitaxel-resistant; Epi-R: epirubicin-resistant; NES: normalized enrichment score.